Literature DB >> 34248463

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021.

Marc Thill1, Michael Friedrich2, Cornelia Kolberg-Liedtke3, Ute-Susann Albert4, Maggie Banys-Paluchowski5,6, Ingo Bauerfeind7, Jens-Uwe Blohmer8, Wilfried Budach9, Peter Dall10, Eva M Fallenberg11, Peter A Fasching12, Tanja Fehm13, Bernd Gerber14, Oleg Gluz15, Nadia Harbeck16, Jörg Heil17, Jens Huober6, Christian Jackisch18, Hans-Heinrich Kreipe19, David Krug20, Thorsten Kühn21, Sherko Kümmel22, Sibylle Loibl23, Diana Lüftner24, Michael P Lux25, Nicolai Maass26, Christoph Mundhenke1, Ulrike Nitz15, Tjoung-Won Park-Simon2, Toralf Reimer14, Kerstin Rhiem3, Achim Rody5, Marcus Schmidt4, Andreas Schneeweiss5, Florian Schütz7, Hans-Peter Sinn8, Christine Solbach9, Erich-Franz Solomayer11, Elmar Stickeler12, Christoph Thomssen13, Michael Untch14, Isabell Witzel15, Achim Wöckel4, Volkmar Müller15, Wolfgang Janni16, Nina Ditsch17.   

Abstract

Entities:  

Year:  2021        PMID： 34248463      PMCID： PMC8248779          DOI： 10.1159/000516420

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.268


× No keyword cloud information.
  34 in total

1.  Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.

Authors:  Matthias Christgen; Stephan Bartels; Angelina Luft; Sascha Persing; Daniel Henkel; Ulrich Lehmann; Hans Kreipe
Journal:  Virchows Arch       Date:  2018-08-09       Impact factor: 4.064

2.  Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis.

Authors:  Y Tesfamariam; T Jakob; A Wöckel; A Adams; A Weigl; I Monsef; K Kuhr; N Skoetz
Journal:  Crit Rev Oncol Hematol       Date:  2019-02-19       Impact factor: 6.312

3.  International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer.

Authors:  Nancy U Lin; Christoph Thomssen; Fatima Cardoso; David Cameron; Tanja Cufer; Lesley Fallowfield; Prudence A Francis; Stella Kyriakides; Olivia Pagani; Elzbieta Senkus; Alberto Costa; Eric P Winer
Journal:  Breast       Date:  2013-04-17       Impact factor: 4.380

4.  Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.

Authors:  Atilla Soran; Vahit Ozmen; Serdar Ozbas; Hasan Karanlik; Mahmut Muslumanoglu; Abdullah Igci; Zafer Canturk; Zafer Utkan; Cihangir Ozaslan; Turkkan Evrensel; Cihan Uras; Erol Aksaz; Aykut Soyder; Umit Ugurlu; Cavit Col; Neslihan Cabioglu; Betül Bozkurt; Ali Uzunkoy; Neset Koksal; Bahadir M Gulluoglu; Bulent Unal; Can Atalay; Emin Yıldırım; Ergun Erdem; Semra Salimoglu; Atakan Sezer; Ayhan Koyuncu; Gunay Gurleyik; Haluk Alagol; Nalan Ulufi; Uğur Berberoglu; Mustafa Dulger; Omer Cengiz; Efe Sezgin; Ronald Johnson
Journal:  Ann Surg Oncol       Date:  2018-05-17       Impact factor: 5.344

5.  TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

Authors:  Nadine M Tung; Mark E Robson; Steffen Ventz; Cesar A Santa-Maria; Rita Nanda; Paul K Marcom; Payal D Shah; Tarah J Ballinger; Eddy S Yang; Shaveta Vinayak; Michelle Melisko; Adam Brufsky; Michelle DeMeo; Colby Jenkins; Susan Domchek; Alan D'Andrea; Nancy U Lin; Melissa E Hughes; Lisa A Carey; Nick Wagle; Gerburg M Wulf; Ian E Krop; Antonio C Wolff; Eric P Winer; Judy E Garber
Journal:  J Clin Oncol       Date:  2020-10-29       Impact factor: 44.544

6.  Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

Authors:  Dennis J Slamon; Patrick Neven; Stephen Chia; Peter A Fasching; Michelino De Laurentiis; Seock-Ah Im; Katarina Petrakova; Giulia V Bianchi; Francisco J Esteva; Miguel Martín; Arnd Nusch; Gabe S Sonke; Luis De la Cruz-Merino; J Thaddeus Beck; Xavier Pivot; Manu Sondhi; Yingbo Wang; Arunava Chakravartty; Karen Rodriguez-Lorenc; Tetiana Taran; Guy Jerusalem
Journal:  N Engl J Med       Date:  2019-12-11       Impact factor: 91.245

Review 7.  Malignant Pleural Effusion: Diagnosis and Management.

Authors:  Lucía Ferreiro; Juan Suárez-Antelo; José Manuel Álvarez-Dobaño; María E Toubes; Vanessa Riveiro; Luis Valdés
Journal:  Can Respir J       Date:  2020-09-23       Impact factor: 2.409

8.  Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Authors:  Ahmad Awada; Ramon Colomer; Kenichi Inoue; Igor Bondarenko; Rajendra A Badwe; Georgia Demetriou; Soo-Chin Lee; Ajay O Mehta; Sung-Bae Kim; Thomas Bachelot; Chanchal Goswami; Suryanarayan Deo; Ron Bose; Alvin Wong; Feng Xu; Bin Yao; Richard Bryce; Lisa A Carey
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777

9.  The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.

Authors:  George W Sledge; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; PierFranco Conte; Yi Lu; Susana Barriga; Karla Hurt; Martin Frenzel; Stephen Johnston; Antonio Llombart-Cussac
Journal:  JAMA Oncol       Date:  2020-01-01       Impact factor: 31.777

10.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).

Authors:  F Cardoso; S Paluch-Shimon; E Senkus; G Curigliano; M S Aapro; F André; C H Barrios; J Bergh; G S Bhattacharyya; L Biganzoli; F Boyle; M-J Cardoso; L A Carey; J Cortés; N S El Saghir; M Elzayat; A Eniu; L Fallowfield; P A Francis; K Gelmon; J Gligorov; R Haidinger; N Harbeck; X Hu; B Kaufman; R Kaur; B E Kiely; S-B Kim; N U Lin; S A Mertz; S Neciosup; B V Offersen; S Ohno; O Pagani; A Prat; F Penault-Llorca; H S Rugo; G W Sledge; C Thomssen; D A Vorobiof; T Wiseman; B Xu; L Norton; A Costa; E P Winer
Journal:  Ann Oncol       Date:  2020-09-23       Impact factor: 32.976
View more
  4 in total

1.  ABC6 Consensus: Assessment by a Group of German Experts.

Authors:  Diana Lüftner; Peter A Fasching; Renate Haidinger; Nadia Harbeck; Christian Jackisch; Volkmar Müller; Eva Schumacher-Wulf; Christoph Thomssen; Michael Untch; Rachel Würstlein
Journal:  Breast Care (Basel)       Date:  2022-01-20       Impact factor: 2.860

Review 2.  [Management of immune-related adverse events (irAEs) - what needs to be respected?]

Authors:  Christoph Thomssen
Journal:  Gynakologe       Date:  2022-04-26

3.  Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer.

Authors:  Bahriye Aktas; Tanja N Fehm; Manfred Welslau; Volkmar Müller; Diana Lüftner; Florian Schütz; Peter A Fasching; Wolfgang Janni; Christoph Thomssen; Isabell Witzel; Erik Belleville; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Michael P Lux; Maggie Banys-Paluchowski; Cornelia Kolberg-Liedtke; Andreas D Hartkopf; Achim Wöckel; Hans-Christian Kolberg; Elmar Stickeler; Nadia Harbeck; Andreas Schneeweiss
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-09-13       Impact factor: 2.754

4.  Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.

Authors:  Tobias Engler; Peter A Fasching; Diana Lüftner; Andreas D Hartkopf; Volkmar Müller; Hans-Christian Kolberg; Peyman Hadji; Hans Tesch; Lothar Häberle; Johannes Ettl; Markus Wallwiener; Matthias W Beckmann; Alexander Hein; Erik Belleville; Sabrina Uhrig; Pauline Wimberger; Carsten Hielscher; Christian M Kurbacher; Rachel Wuerstlein; Michael Untch; Florin-Andrei Taran; Hans-Martin Enzinger; Petra Krabisch; Manfred Welslau; Michael Maasberg; Dirk Hempel; Michael P Lux; Laura L Michel; Wolfgang Janni; Diethelm Wallwiener; Sara Y Brucker; Tanja N Fehm; Andreas Schneeweiss
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-07-12       Impact factor: 2.754
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.